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ERRATUM
In the article by Fukui T, Sakakura N, Mori S, et al, “Controversy about Small Peripheral Lung Adenocarcinomas: How
Should We Manage Them?”, J Thorac Oncol 2:546–552, 2007 the authors neglected to reference the publication by
Garfield DH, Cadranel JL, Wislez M, et al, The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum
of Disease, J Thorac Oncol 1:344–359, 2006 which was a valuable resource for their article. The authors regret this error.
Fukui T, Sakakura N, Mori S, et al. Controversy about Small Peripheral Lung Andenocarcinomas: How Should We Manage
Them? J Thorac Oncol. 2007;2:546–552.
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